AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Compounding the robust improvements in sales, AbbVie raised its profitability guidance for the full year. It now expects to post adjusted per-share earnings of $12.09 to $12.29; previously it was ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at ...

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

Sector weakness in some FTSE 100 industries has also left some of my long-term favourite stocks offering attractive dividend ...

The BT share price has been steadily climbing back since newish boss Allison Kirkby came on board. Is the new optimism ...

Baloise's largest investor has sold its stake to Helvetia's top shareholder, days after the Swiss insurers announced a merger to create a group with a combined market value of around 18 billion Swiss ...

Prefs sit somewhere between shares and bonds. They are issued by companies and promise a fixed dividend, set as a percentage ...